TY - JOUR AU - Kitabachi, A. E. AU - Umpierrez, G. E. AU - Miles, J. M. AU - Fisher, J. N. PY - 2009 DA - 2009// TI - Hyperglycemic crisis in adults with diabetes JO - Diabetes Care VL - 32 UR - https://doi.org/10.2337/dc09-9032 DO - 10.2337/dc09-9032 ID - Kitabachi2009 ER - TY - JOUR AU - Munro, J. F. AU - Campbell, I. W. AU - McCuish, A. C. AU - Duncan, L. J. PY - 1973 DA - 1973// TI - Euglycemic diabetic ketoacidosis JO - Br Med J VL - 2 UR - https://doi.org/10.1136/bmj.2.5866.578 DO - 10.1136/bmj.2.5866.578 ID - Munro1973 ER - TY - JOUR AU - Modi, A. AU - Agrawal, A. AU - Morgan, F. PY - 2017 DA - 2017// TI - Euglycemic ketoacidosis: a review JO - Curr Diabetes Rev VL - 13 UR - https://doi.org/10.2174/1573399812666160421121307 DO - 10.2174/1573399812666160421121307 ID - Modi2017 ER - TY - STD TI - Rawla P, Vellipuram AR, Bandaru SS, Predeep Raj J. Euglycemic diabetes ketoacidosis: a diagnostic and therapeutic dilemma. Endocrinol Diabetes Metab Case Rep. 2017. https://doi.org/10.1530/EDM-17-0081. ID - ref4 ER - TY - STD TI - FDA news release. FDA approves Invokana to treat type 2 diabetes. https://wayback.archive-it.org/7993/20170112023858/https://www.fda.gov/NewsEvents/Newsroom/PressAnnounce-ments/ucm345848.htm. Accessed 8 Mar 2019. UR - https://wayback.archive-it.org/7993/20170112023858/https://www.fda.gov/NewsEvents/Newsroom/PressAnnounce-ments/ucm345848.htm ID - ref5 ER - TY - STD TI - Drug safety announcement. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. https://www.fda.gov/downloads/drugs/drugsafety/ucm446954.pdf. Accessed 10 Mar 2019. UR - https://www.fda.gov/downloads/drugs/drugsafety/ucm446954.pdf ID - ref6 ER - TY - STD TI - EMA confirms recommendations to minimize ketoacidosis risk with SGLT2 inhibitors for diabetes. https://www.ema.europa.eu/en/medicines/human/referrals/sglt2-inhibitors. Accessed 25 Feb 2019. UR - https://www.ema.europa.eu/en/medicines/human/referrals/sglt2-inhibitors ID - ref7 ER - TY - JOUR AU - Blau, J. e. n. n. y. E. AU - Tella, S. r. i. H. a. r. s. h. a. AU - Taylor, S. i. m. e. o. n. I. AU - Rother, K. r. i. s. t. i. n. a. I. PY - 2017 DA - 2017// TI - Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data JO - Diabetes/Metabolism Research and Reviews VL - 33 UR - https://doi.org/10.1002/dmrr.2924 DO - 10.1002/dmrr.2924 ID - Blau2017 ER - TY - JOUR AU - Garber, A. J. AU - Abrahamson, M. J. AU - Barzilay, J. I. AU - Blonde, L. AU - Bloomgarden, Z. T. AU - Bush, M. A. PY - 2019 DA - 2019// TI - Consensus statement by the American Association of Clinical Endocrinologist and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2019 executive summary JO - Endocr Pract VL - 25 UR - https://doi.org/10.4158/CS-2018-0535 DO - 10.4158/CS-2018-0535 ID - Garber2019 ER - TY - JOUR AU - Goldenberg, R. M. AU - Berard, L. D. AU - Cheng, A. Y. Y. AU - Gilbert, J. D. AU - Verma, S. AU - Woo, V. C. PY - 2016 DA - 2016// TI - SGLT2 inhibitor - associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis JO - Clin Ther VL - 38 UR - https://doi.org/10.1016/j.clinthera.2016.11.002 DO - 10.1016/j.clinthera.2016.11.002 ID - Goldenberg2016 ER - TY - JOUR AU - Zelniker, T. A. AU - Wiviott, S. D. AU - Raz, I. AU - Im, K. AU - Goodrich, E. L. AU - Bonaca, M. P. PY - 2019 DA - 2019// TI - SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials JO - Lancet. VL - 393 UR - https://doi.org/10.1016/S0140-6736(18)32590-X DO - 10.1016/S0140-6736(18)32590-X ID - Zelniker2019 ER - TY - JOUR AU - Wu, J. H. AU - Foote, C. AU - Blomster, J. AU - Toyama, T. AU - Perkovic, V. AU - Sundstrom, J. PY - 2016 DA - 2016// TI - Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis JO - Lancet Diabetes Endocrinol VL - 4 UR - https://doi.org/10.1016/S2213-8587(16)00052-8 DO - 10.1016/S2213-8587(16)00052-8 ID - Wu2016 ER - TY - JOUR AU - Whalen, K. AU - Miller, S. AU - Onge, E. S. PY - 2015 DA - 2015// TI - The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes JO - Clin Ther VL - 37 UR - https://doi.org/10.1016/j.clinthera.2015.03.004 DO - 10.1016/j.clinthera.2015.03.004 ID - Whalen2015 ER - TY - JOUR AU - Bonner, C. AU - Kerr-Conte, J. AU - Gmyr, V. AU - Queniat, G. AU - Moerman, E. AU - Thevenet, J. PY - 2015 DA - 2015// TI - Inhibition of glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion JO - Nat Med VL - 21 UR - https://doi.org/10.1038/nm.3828 DO - 10.1038/nm.3828 ID - Bonner2015 ER - TY - JOUR AU - Henry, R. R. AU - Thakkar, P. AU - Tong, C. AU - Polidori, D. AU - Alba, M. PY - 2015 DA - 2015// TI - Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type I diabetes JO - Diabetes Care VL - 38 UR - https://doi.org/10.2337/dc15-1730 DO - 10.2337/dc15-1730 ID - Henry2015 ER - TY - JOUR AU - Zinman, B. AU - Wanner, C. AU - Lachin, J. M. AU - Fitchett, D. AU - Bluhmki, E. AU - Hantel, S. PY - 2015 DA - 2015// TI - Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504720 DO - 10.1056/NEJMoa1504720 ID - Zinman2015 ER - TY - JOUR AU - Erondu, N. AU - Desai, M. AU - Ways, K. AU - Meininger, G. PY - 2015 DA - 2015// TI - Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program JO - Diabetes Care VL - 38 UR - https://doi.org/10.2337/dc15-1251 DO - 10.2337/dc15-1251 ID - Erondu2015 ER - TY - JOUR AU - Dizon, S. AU - Keely, E. J. AU - Malcolm, J. AU - Arnaout, A. PY - 2017 DA - 2017// TI - Insights into the recognition and management of SGLT2-inhibitor-associated ketoacidosis: it’s not just euglycemic diabetic ketoacidosis JO - Can J Diabetes VL - 41 UR - https://doi.org/10.1016/j.jcjd.2017.05.004 DO - 10.1016/j.jcjd.2017.05.004 ID - Dizon2017 ER - TY - JOUR AU - Fadini, G. P. AU - Bonora, B. M. AU - Avogaro, A. PY - 2017 DA - 2017// TI - SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA adverse event reporting system JO - Diabetologia. VL - 60 UR - https://doi.org/10.1007/s00125-017-4301-8 DO - 10.1007/s00125-017-4301-8 ID - Fadini2017 ER - TY - JOUR AU - Misaghian-Xanthos, N. AU - Shariff, A. I. AU - Mekala, K. AU - Fearrington, L. R. AU - Setji, T. L. AU - Aloi, J. A. PY - 2017 DA - 2017// TI - Sodium-glucose transporter 2 inhibitors and diabetic ketoacidosis: a case series from three academic institutions JO - Diabetes Care VL - 40 UR - https://doi.org/10.2337/dc16-2591 DO - 10.2337/dc16-2591 ID - Misaghian-Xanthos2017 ER - TY - JOUR AU - Handelsman, Y. AU - Henry, R. R. AU - Bloomgarden, Z. T. AU - Dagogo-Jack, S. AU - Defronzo, R. A. AU - Einhorn, D. PY - 2016 DA - 2016// TI - American Association of Clinical Endocrinologists and American College of Endocrinology position paper on the association of SGLT-2 inhibitors and diabetic ketoacidosis JO - Endocr Pract VL - 22 UR - https://doi.org/10.4158/EP161292.PS DO - 10.4158/EP161292.PS ID - Handelsman2016 ER - TY - JOUR AU - Burke, K. R. AU - Schumacher, C. A. AU - Harpe, S. E. PY - 2017 DA - 2017// TI - SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature JO - Pharmacotherapy. VL - 37 UR - https://doi.org/10.1002/phar.1881 DO - 10.1002/phar.1881 ID - Burke2017 ER - TY - STD TI - Drug safety communications. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. https://www.fda.gov/downloads/drugs/drugsafety/ucm475487.pdf. Accessed 14 Mar 2019. UR - https://www.fda.gov/downloads/drugs/drugsafety/ucm475487.pdf ID - ref23 ER - TY - JOUR AU - Peters, A. L. AU - Buschur, E. O. AU - Buse, J. B. AU - Cohan, P. AU - Diner, J. C. AU - Hirsh, I. B. PY - 2015 DA - 2015// TI - Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition JO - Diabetes Care VL - 38 UR - https://doi.org/10.2337/dc15-0843 DO - 10.2337/dc15-0843 ID - Peters2015 ER - TY - JOUR AU - Ogawa, W. AU - Sakaguchi, K. PY - 2016 DA - 2016// TI - Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors JO - J Diabetes Investig VL - 7 UR - https://doi.org/10.1111/jdi.12401 DO - 10.1111/jdi.12401 ID - Ogawa2016 ER - TY - JOUR AU - Jenkins, D. AU - Close, C. F. AU - Krentz, A. J. AU - Nattrass, M. AU - Wright, A. D. PY - 1993 DA - 1993// TI - Euglycemic diabetic ketoacidosis: does it exist? JO - Acta Diabetol VL - 30 UR - https://doi.org/10.1007/BF00569937 DO - 10.1007/BF00569937 ID - Jenkins1993 ER - TY - JOUR AU - Benoit, S. R. AU - Zhang, Y. AU - Giess, L. S. AU - Gregg, E. W. AU - Albright, A. PY - 2018 DA - 2018// TI - Trends in diabetic ketoacidosis hospitalizations and in-house mortality – United States, 2000-2014 JO - MMWR Morb Mortal Wkly Rep VL - 67 UR - https://doi.org/10.15585/mmwr.mm6712a3 DO - 10.15585/mmwr.mm6712a3 ID - Benoit2018 ER -